The global retinoblastoma treatment market size was estimated to be USD 2.62 billion in 2023 and is expected to reach USD 4.20 billion by 2034 with a CAGR of 4.38% during the forecast period 2024-2034. Rising incidence of retinoblastoma, early diagnosis and treatment, increasing healthcare expenditure, growing awareness of retinoblastoma treatment options, development of new treatments, and government initiatives will drive the market growth. The many retinoblastoma therapy options are becoming more well-known. Campaigns to raise public awareness and the proliferation of internet information are to blame for this. Consequently, a greater number of patients are pursuing therapy for retinoblastoma, thereby propelling market expansion.
Children are the main victims of retinoblastoma, an uncommon eye malignancy. On the other hand, retinoblastoma incidence is rising, especially in developing nations. This can be attributed to several variables, such as enhanced methods for screening and diagnosis and heightened public knowledge of the illness. For instance, in October 2023 Novartis AG announced favorable Phase II research findings for IPI-545, indicating potential tolerance and effectiveness in the treatment of retinoblastoma.
By treatment type, the chemotherapy segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the advancements in chemotherapy protocols, the introduction of targeted therapies, and the increasing adoption of personalized treatment regimens tailored to the genetic characteristics of individual patients. For instance, Roche Holding AG presented preclinical findings on RG7816 at the American Association for Cancer Research (AACR) meeting in April 2023, indicating promise for treating retinoblastoma. Additionally, the targeted therapies and gene therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing understanding of the molecular mechanisms underlying retinoblastoma, leading to the development of more precise and effective targeted therapies.
By type of retinoblastoma, the non-hereditary retinoblastoma segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the increased prevalence of non-hereditary retinoblastoma cases, early detection strategies, and the development of tailored treatment approaches specifically designed for this segment of patients. Pfizer Inc. Launched Zirabev (bevacizumab) biosimilar in India in September 2023, offering a more affordable option for treating retinoblastoma-related eye conditions. Additionally, the hereditary retinoblastoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of genetic predisposition, advancements in genetic testing technologies, and a growing trend toward personalized treatment strategies.
By type of staging, the intraocular retinoblastoma segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the advancements in early diagnosis techniques, improved treatment outcomes, and a growing emphasis on preserving vision through intraocular therapies. For instance, Roche Holding AG presented preclinical findings on RG7816 at the American Association for Cancer Research (AACR) meeting in April 2023, indicating promise for treating retinoblastoma. Additionally, the extraocular retinoblastoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in multidisciplinary treatment approaches, including neoadjuvant chemotherapy, targeted therapies, and innovative surgical interventions designed to address the complexities associated with extraocular retinoblastoma.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the central role of hospitals as primary healthcare facilities for diagnosis, treatment, and management of retinoblastoma cases. For instance, Merck & Co., Inc. received FDA clearance in August 2023 for Keytruda in conjunction with chemotherapy for the treatment of mismatch repair-deficient (MMRd) solid tumors, including certain retinoblastoma patients. Additionally, the specialty eye clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on specialized and targeted care for retinoblastoma patients, the rising demand for precise ophthalmic interventions, and the establishment of dedicated eye care facilities.
North American region is anticipated for the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, well-established research and development initiatives, and a high prevalence of retinoblastoma awareness programs. For instance, in June 2023, Sanofi announced a relationship with a patient advocacy organization to promote awareness of retinoblastoma and support research initiatives. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing healthcare awareness, a rising prevalence of retinoblastoma cases, and ongoing efforts to improve healthcare infrastructure.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Children are the main victims of retinoblastoma, an uncommon eye malignancy. On the other hand, retinoblastoma incidence is rising, especially in developing nations. This can be attributed to several variables, such as enhanced methods for screening and diagnosis and heightened public knowledge of the illness. For instance, in October 2023 Novartis AG announced favorable Phase II research findings for IPI-545, indicating potential tolerance and effectiveness in the treatment of retinoblastoma.
By treatment type, the chemotherapy segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the advancements in chemotherapy protocols, the introduction of targeted therapies, and the increasing adoption of personalized treatment regimens tailored to the genetic characteristics of individual patients. For instance, Roche Holding AG presented preclinical findings on RG7816 at the American Association for Cancer Research (AACR) meeting in April 2023, indicating promise for treating retinoblastoma. Additionally, the targeted therapies and gene therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing understanding of the molecular mechanisms underlying retinoblastoma, leading to the development of more precise and effective targeted therapies.
By type of retinoblastoma, the non-hereditary retinoblastoma segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the increased prevalence of non-hereditary retinoblastoma cases, early detection strategies, and the development of tailored treatment approaches specifically designed for this segment of patients. Pfizer Inc. Launched Zirabev (bevacizumab) biosimilar in India in September 2023, offering a more affordable option for treating retinoblastoma-related eye conditions. Additionally, the hereditary retinoblastoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of genetic predisposition, advancements in genetic testing technologies, and a growing trend toward personalized treatment strategies.
By type of staging, the intraocular retinoblastoma segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the advancements in early diagnosis techniques, improved treatment outcomes, and a growing emphasis on preserving vision through intraocular therapies. For instance, Roche Holding AG presented preclinical findings on RG7816 at the American Association for Cancer Research (AACR) meeting in April 2023, indicating promise for treating retinoblastoma. Additionally, the extraocular retinoblastoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in multidisciplinary treatment approaches, including neoadjuvant chemotherapy, targeted therapies, and innovative surgical interventions designed to address the complexities associated with extraocular retinoblastoma.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global retinoblastoma treatment market in 2023 owing to the central role of hospitals as primary healthcare facilities for diagnosis, treatment, and management of retinoblastoma cases. For instance, Merck & Co., Inc. received FDA clearance in August 2023 for Keytruda in conjunction with chemotherapy for the treatment of mismatch repair-deficient (MMRd) solid tumors, including certain retinoblastoma patients. Additionally, the specialty eye clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on specialized and targeted care for retinoblastoma patients, the rising demand for precise ophthalmic interventions, and the establishment of dedicated eye care facilities.
North American region is anticipated for the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, well-established research and development initiatives, and a high prevalence of retinoblastoma awareness programs. For instance, in June 2023, Sanofi announced a relationship with a patient advocacy organization to promote awareness of retinoblastoma and support research initiatives. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to increasing healthcare awareness, a rising prevalence of retinoblastoma cases, and ongoing efforts to improve healthcare infrastructure.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by treatment type, type of retinoblastoma, type of staging, end-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Retinoblastoma Treatment Market Report 2023 - 2034
Retinoblastoma Treatment Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Surgery
- Radiation therapy
- Laser therapy
- Cryotherapy
- Chemotherapy
- Bone Marrow Transplantation/Stem Cell Transplant
- Targeted Therapies and Gene Therapy
Retinoblastoma Treatment Market Analysis & Forecast by Type of Retinoblastoma 2023 - 2034 (Revenue USD Bn)
- Non-hereditary Retinoblastoma
- Hereditary Retinoblastoma
Retinoblastoma Treatment Market Analysis & Forecast by Type of Staging 2023 - 2034 (Revenue USD Bn)
- Intraocular Retinoblastoma
- Extraocular Retinoblastoma
Retinoblastoma Treatment Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Cancer Treatment Centre
- Specialty Eye Clinics
Retinoblastoma Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Retinoblastoma Treatment Type Market: Treatment Type Estimates & Trend Analysis
8. Retinoblastoma Treatment Type Market: Type of Retinoblastoma Estimates & Trend Analysis
9. Retinoblastoma Treatment Type Market: Type of Staging Estimates & Trend Analysis
10. Retinoblastoma Treatment Type Market: End-User Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Retinoblastoma Treatment Type Market
13. Europe Global Retinoblastoma Treatment Type Market
14. Asia Pacific Global Retinoblastoma Treatment Type Market
15. Latin America Global Retinoblastoma Treatment Type Market
16. MEA Global Retinoblastoma Treatment Type Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Johnson & Johnson
- AbbVie Inc.
- AstraZeneca
- Bayer AG
- Genentech (a member of the Roche Group)
- Takeda Pharmaceutical Company Limited
- Celgene Corporation (acquired by Bristol Myers Squibb)
- Amgen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.62 Billion |
| Forecasted Market Value ( USD | $ 4.2 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
